Phosphate overload accelerates vascular aging in uremic patients by COZZOLINO, MARIO et al.
1826-1868/006-6$15.00/0
INTRODUCTION
Vascular calcification is a common event in patients
affected by diabetes and chronic kidney disease (CKD)
(1, 2). In fact, these patients develop extensive medial
calcification, which causes increased arterial stiffness
and high morbidity and mortality due to cardiovascular
events (3). Calcification of soft tissues and blood vessel
walls occurs frequently in dialyzed patients compared
to the non-uremic population (4-6). A growing number
of risk factors are associated with vascular mineraliza-
tion in dialysis patients (inflammation, age, time on dial-
ysis, etc.), but abnormalities in bone mineral metabo-
lism represent a major determinant (Tab. I). Clearly, hy-
perphosphatemia, elevated serum calcium-phosphate
product levels, and secondary hyperparathyroidism are
associated to vascular calcification, although their roles
have been incompletely investigated (7, 8). 
In addition to these classic alterations in bone and
mineral metabolism, an active process has been docu-
mented (9). Enhanced serum phosphate levels have
been recently investigated as inducing factors on extra-
skeletal calcification in uremic population. In particular,
elevated blood levels of phosphate associate with ec-
topic calcifications and increased risk of calciphylaxis
(10-12). In vitro studies demonstrated that human aortic
smooth muscle cells calcify when incubated in a high
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the pathogenesis of vascular mineralization in uremic patients and also appear to be associated
with increased cardiovascular mortality. Together with classical passive precipitation of calcium-
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phate may cause extraskeletal calcification directly through a real “ossification” of the tunica
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TABLE I - RISK FACTORS FOR CARDIOVASCULAR DISEASE IN
CHRONIC RENAL FAILURE PATIENTS
Classic Typical
Obesity Secondary hyperparathyroidism
Family history Hyperphosphatemia
Smoking Inflammation
Hypertension Hyperhomocysteinemia
Diabetes
Dyslipidemia
GenderCozzolino et al
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phosphate medium, where calcium and calcitriol are not
changed (13). 
In the last decade, several studies defined calcifica-
tion of atherosclerotic lesions as an active process sim-
ilar to bone formation. Furthermore, vascular calcifica-
tion was shown to involve not only a passive calcium-
phosphate deposition on atherosclerotic vessels but al-
so an active “ossification” of vascular structures. 
Since vascular calcifications are predictive of higher
morbidity and mortality, the control of serum phospho-
rus in CKD patients becomes crucial in preventing in-
creases in calcium-phosphate product, secondary hy-
perparathyroidism, and so far vascular mineralization
(14). Recent studies have shown that new pharmaco-
logical tools may be useful to prevent vascular calcifica-
tions in animals and humans (15-17). 
In this review, we analyzed the role of phosphate on
inducing vascular mineralization in CKD patients.
Cardiovascular risk in uremic patients
Abnormalities in mineral and bone metabolism are
very common in end-stage renal disease patients. In
this population, parathyroid hyperplasia and enhanced
secretion of PTH characterize secondary hyperparathy-
roidism (18). Parathyroid gland enlargement and high
circulating levels of PTH (19) are major contributors to
increased bone resorption, a feature of renal osteodys-
trophy. Hypocalcemia, hyperphosphatemia, and vitamin
D deficiency are the main regulators of hyperparathy-
roidism secondary to renal failure (20).
In the last decade, large evidence has been accumu-
lated indicating that disturbances in mineral and bone
metabolism in chronic renal disease patients associate
with increased morbidity and mortality. In fact, cardio-
vascular events are the most frequent cause of death in
patients with chronic renal failure (3). Calcification of
soft tissues and blood vessel walls (Fig. 1) occurs fre-
quently in dialyzed patients compared to the non-ure-
mic population (21). Hyperphosphatemia and increased
calcium-phosphate product are important contributors
to vascular calcifications in uremic patients and also
appear to be associated with increased mortality (7). In
particular, elevated blood levels of phosphate associate
with ectopic calcifications and increased risk of calci-
phylaxis (12). Unfortunately, the pathogenic effects of
hyperphosphatemia, high calcium-phosphate product,
and secondary hyperparathyroidism on enhancing vas-
cular calcification in chronic renal failure are still poorly
Fig. 1 - Vascular calcification in CKD. A representative hemodialysis patient with remarkable bilateral carotid artery calcifications. Doppler
analysis revealed a 60% stenosis in the left carotid artery (a) and a 70% stenosis in the contralateral artery (b). The patient had a sudden
death 5 months after this CT scan was performed.
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understood. 
Since vascular calcifications are predictive of higher
morbidity and mortality, the control of serum phosphorus
in patients with chronic renal failure is crucial in preventing
increases in calcium-phosphate product, secondary hy-
perparathyroidism, and so far ectopic calcifications (12).
In the past, the standard treatment for the hyperphos-
phatemia of chronic renal failure consisted of dietary
phosphate restriction, dialysis treatment efficiency, and
administration of phosphate-binders (aluminum salts, cal-
cium carbonate or acetate). Recent studies described the
limitations of calcium salts as phosphate-binders and the
elevated calcium load in patients with advanced renal fail-
ure (14). Moreover, with such therapeutic approach more
than 50% of patients did not achieve a good control of
serum phosphate levels. 
Recently, new phosphate binders, that do not contain
aluminum or calcium, and therefore lack the side effects
associated with classical phosphate-binders, opened
new perspectives in preventing ectopic calcification in
end-stage renal disease. Recent studies have shown
that new therapeutical tools may be useful to prevent
vascular calcifications in animals and humans (17). 
Active regulation of vascular mineralization by
phosphate
During the last decade, several investigators have
been deeply interested in studying the mechanisms of
vascular calcification (22). In fact, extraskeletal mineral-
ization seems to be characterized not only by a passive
calcium-phosphate deposition in the vasculature, but
also by an active transformation of arterial walls in bone
structures  regulated  by  genes  associated  with  os-
teoblastic  functions  (7).  Moreover,  recent  studies
demonstrated phosphate regulation of vascular calcifi-
cation and provide some insights into the mechanisms
for phosphate–induction of metastatic calcifications.
Jono et al (13, 23) showed that high phosphorus levels
in the incubation media (2 mmol/L) increased human
aortic  smooth  muscle  cells  (HSMCs)  calcification.
Phosphate-containing mineral deposition was predomi-
nant in the extracellular matrix (13). Furthermore, these
in vitro studies indicated that high phosphate directly
increases HSMCs calcification by inducing the expres-
sion of the sodium-phosphate cotransporter Pit-1 and
the osteoblast-specific genes Osf2/Cbfa-1 (13). Cbfa-1
is a transcription factor that regulates the expression of
osteocalcin (24), one of the key osteoblast-specific
genes in vitro and in vivo.
Other studies identified a potential role of phosphate
on “active” regulation of vascular calcification. In vivo
studies by Kuro-o et al (25) illustrate a 2-fold increase in
serum phosphate levels in the KLOTHO-gene mutant
mice, resulted in increased calcium-phosphate product
with the development of vascular calcifications and os-
teoporosis, in the presence of normal renal function.
Further evidence has been reported on the function
and action of a bone-associated protein: osteopontin.
In two recent studies, Wada et al (26) proposed that os-
teopontin acts as an inhibitor of calcification of vascular
smooth muscle cell (VSMC) cultures, while Jono et al
(27) demonstrated that the phosphorylation of osteo-
pontin was a mandatory step to inhibit VSMCs calcifi-
cation. Thus, osteopontin is both an important bone
mineralization modulator and a potent inhibitor of ex-
traskeletal mineralization. In very recent review article,
Giachelli et al (28) analyzed the opposite roles of phos-
phate and osteopontin on regulating vascular calcifica-
tion. In fact, while phosphate induces directly vascular
smooth muscle cell mineralization, osteopontin may
stimulate cellular mineral resorption and inhibit calci-
um-phosphate deposition. Furthermore, smooth mus-
cle cells isolated from osteopontin knock-out mice
(OPN -/-) have a significantly higher calcification grade
when they are incubated in a medium containing elevat-
ed concentrations of inorganic phosphate (29).
In summary, several studies support an active role of
phosphate on regulating arterial mineralization, “simi-
lar” to bone formation. However, new evidence is nec-
essary to better understand pathogenic mechanisms of
vascular calcification in chronic kidney disease, and the
potential role of phosphate on controlling directly this
disease. 
Prevention of uremia-induced extraskeletal
calcification by reducing serum phosphate 
levels
Over the past 40 years, different studies have shown
that phosphate retention not only induces secondary
hyperparathyroidism but also accelerates kidney failureCozzolino et al
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by inducing renal calcifications (30). Clearly, Gimenez et
al (31) showed that patients with higher serum calcium-
phosphate product, renal calcium content, and histo-
logic calcium deposition were those with serum creati-
nine levels above 1.5 mg/dL. In experimental renal fail-
ure, high dietary phosphate-induced acceleration of
kidney function deterioration is associated with renal
calcium-phosphate deposition and tubular-interstitial
damage (32). 
The control of serum phosphorus levels is critical in
preventing ectopic calcification in CKD. Recently, using
an experimental model of chronic renal failure, we com-
pared the effects of sevelamer hydrochloride, a non-
calcaemic phosphate-binder, and calcium carbonate in
the  control  of  serum  phosphate,  secondary  hyper-
parathyroidism, and ectopic calcifications (33). Seve-
lamer-treated rats showed a significant reduction of re-
nal calcium deposition compared to both uremic un-
treated animals and rats taking calcium carbonate. In
addition, in long-term experimental chronic renal failure,
the phosphate-binder sevelamer controls serum phos-
phorus and secondary hyperparathyroidism, and great-
ly attenuates vascular calcification (34).
In humans, cardiovascular calcification often occurs
with advanced age, atherosclerosis, and diabetes melli-
tus. Several studies showed a higher prevalence of
coronary plaques in dialyzed patients compared to the
non-uremic population (10, 21). In addition, vascular al-
terations in CKD are associated with accelerated ather-
osclerosis and vascular stiffening, and left ventricular
hypertrophy which are major causes of cardiovascular
mortality in hemodialysis patients (3). Both accelerated
atherosclerosis and mineralization of arterial intima and
media caused arterial stiffness and hypertension (35).  
Increases in serum phosphate and calcium-phos-
phate product levels are associated with arterial calcifi-
cation in renal failure. Ongoing evidence demonstrates
that  calcium-containing  phosphate-binders  can  in-
crease calcium load. A new non-invasive imaging tech-
nology, electron beam computed tomography (EBCT),
demonstrated that both hyperphosphatemia and in-
creased calcium-phosphate product cause a progres-
sive increase in calcium deposition in the coronary ar-
teries, mitral and aortic valves in patients with advanced
renal failure (10). A study of adolescents and young
adult hemodialysis patients by Goodman et al (11) not-
ed a correlation between coronary artery calcification
detected by EBCT and duration of dialysis, serum phos-
phorus and calcium-phosphate product levels, and dai-
ly intake of calcium. Another study in 200 hemodialysis
patients by Chertow et al (14) showed that sevelamer
attenuated the progression of coronary and aortic calci-
fication better than calcium-based phosphate binders
after 12 months. Subjects treated with sevelamer had
lower serum calcium, total cholesterol, and LDL levels
compared  to  subjects  treated  with  calcium-based
phosphate binders. 
It should also be kept in mind that a more efficient
dialysis can be of great help in reducing or eliminating
phosphate retention in dialysis patients. Minutolo et al
(36) proved that hemodiafiltration is more effective than
hemodialysis in removing phosphate, without differ-
ences in phosphate levels at the end of dialysis. Pier-
ratos et al (37) showed that with long , nocturnal he-
modialysis (performed six to seven nights per week for
8 to 10 h during sleep at home), weekly removal of
phosphate was twice as high as conventional hemodial-
ysis. Moreover, all patients discontinued their phos-
phate binders and increased dietary phosphate and
protein intake. However, daily hemodialysis is very time-
demanding for patients and is more expensive, so that
at the moment it can be applied to a very limited number
of subjects.
CONCLUSIONS
Hyperphosphatemia is an independent risk factor for
higher incidence of cardiovascular events in patients
with chronic kidney disease. In addition, increased
phosphorus and calcium-phosphate product levels are
important  contributors  to  vascular  calcifications  in
these patients. Also, it is well known how hyperphos-
phatemia accelerates the progression of secondary hy-
perparathyroidism, the concomitant bone loss and con-
sequent calcium-phosphate precipitation. The control
of serum phosphorus levels may reduce vascular calci-
fication by decreasing calcium-phosphate product and
reducing the active process through regulation of spe-
cific genes. Consequently, more efficient phosphate re-
moval by dialysis, along with new calcium-free and alu-
minum-free phosphate binders have been proposed for
the control of hyperphosphatemia in chronic renal fail-
ure. Recent studies have shown that new therapeuti-Vascular calcification in uremia
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cal tools may be useful to prevent vascular calcifica-
tions in animals and humans. Additional investiga-
tions are necessary to examine the relative effect of
different phosphate-binders on mortality for cardio-
vascular events.
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